Guttman-Yassky et al. and Simpson et al. suggested that the management of AD has seen significant advances with IL-13 inhibitors such as lebrikizumab and cendakimab showing strong, dose-dependent improvements in disease severity, itch, and quality of life [44,72]. Here, IL13 is linked to Alzheimer disease.